UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031343
Receipt number R000035780
Scientific Title Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)
Date of disclosure of the study information 2018/02/19
Last modified on 2023/02/02 18:19:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)

Acronym

Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)

Scientific Title

Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)

Scientific Title:Acronym

Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)

Region

Japan


Condition

Condition

AML(acute myeloid leukemia)

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To assess the viability of the clinical sequencing for AML(acute myeloid leukemia) and calculate the rate of the patients with potentially actionable findings by the targeted sequencing analysis.

Basic objectives2

Others

Basic objectives -Others

To assess the viability of the clinical sequencing for AML

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Identification rate of patients with potentially actionable findings(PAF) by introduction of the clinical sequencing.

Key secondary outcomes

Identification rate of the clinically impactful findings (CIF).
The average number of days required to return the genome analysis information to the doctor in charge.
Identification rate of patients in which the genome cannot be analyzed and its causes.
Identification rate of patients that germ cell sequence mutations were identified which are supposed to return the information report.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Age 16-79y at the time of initial diagnosis.
(2) Untreated AML. AML are defined in accordance with the Acute myeloid leukemia (AML) and related neoplasms in WHO classification, 2016 edition.
(3) ECOG performance status score:0-3 and sufficient hepatic, renal, and cardiac function satisfying the laboratory data.
(4) Patients who have the standard anticancer drug treatments.
(5) Patients who provided written informed consent for this study by themselves.
(6) Patients who are under 20 years of age are required to give informed consent by legally acceptable representative.

Key exclusion criteria

(1)APL with PML-RARA, Myeloid sarcoma
(2) Less than 30% of blast and meet the RAEB-t in the FAB classification.
(3)Patients with complications including an activity double cancer, uncontrolled diabetes, and a serious infection.

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Hisayuki
Middle name
Last name Yokoyama

Organization

Tohoku University Graduate School of Medicine

Division name

Department of Hematology

Zip code

980-8574

Address

1-1 Seiryo-machi, Aoba-ku, Sendai-shi, 980-8574, Japan

TEL

022-717-7165

Email

hisayuki.yokoyama.a1@tohoku.ac.jp


Public contact

Name of contact person

1st name Hisayuki
Middle name
Last name Yokoyama

Organization

Tohoku University Graduate School of Medicine

Division name

Department of Hematology

Zip code

980-8574

Address

1-1 Seiryo-machi, Aoba-ku, Sendai-shi, 980-8574, Japan

TEL

+81227177165

Homepage URL

https://www.jalsg.jp/

Email

hisayuki.yokoyama.a1@tohoku.ac.jp


Sponsor or person

Institute

Japan Adult Leukemia Study Group

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee National Hospital Organization Sendai Medical Center

Address

2-8-8 Miyagino, Miyagino-ku, Sendai, Japan

Tel

022-293-1111

Email

syokuin2132@snh.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 02 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 02 Month 15 Day

Date of IRB

2018 Year 02 Month 15 Day

Anticipated trial start date

2018 Year 02 Month 20 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is additional study of "JALSG AML/MDS/CMML Clinical Observational Study (JALSG-CS)-17", and UMIN ID is UMIN000027961.


Management information

Registered date

2018 Year 02 Month 16 Day

Last modified on

2023 Year 02 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035780


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name